person · Reporting owner
SALEKI-GERHARDT AZITA
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | EVP, CHIEF OPERATIONS OFFICER | February 27, 2026 | March 03, 2026 |
| ENTEGRIS INCENTG · Entity 3271 | Director | May 06, 2026 | May 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date February 27, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 197,794 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Tax withholding · Disposed 16,309 · Balance 197,794 |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectProfit sharing trust | 2,706 |
Reported balance
Holding disclosure · report date 2026-02-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,706 F1: Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy spouse | 3,873 |
Reported balance
Holding disclosure · report date 2026-02-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,873 F2: The reporting person disclaims beneficial ownership of all securities held by her spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature.
F2: The reporting person disclaims beneficial ownership of all securities held by her spouse.
ENTEGRIS INC
Report date May 06, 2026 · Filed May 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,383 |
Reported balance
After 2026-05-06 transaction · row 1
1 source rowRow 1 · 2026-05-06 · Grant · Acquired 1,412 · Balance 26,383 F1: These Restricted Stock Units vest in full on the earlier of (1) the first anniversary date of the grant, or (2) the date of the Company's 2027 Annual Meeting of Stockholders. F2: These shares were awarded on May 6, 2026 as Restricted Stock Units, payable solely in Common Stock, pursuant to the Entegris, Inc. 2020 Stock Plan, which provides for the award of Restricted Stock Units to independent directors in consideration for services as such. |
Filing footnotes · ownership attribution and instrument terms
F1: These Restricted Stock Units vest in full on the earlier of (1) the first anniversary date of the grant, or (2) the date of the Company's 2027 Annual Meeting of Stockholders.
F2: These shares were awarded on May 6, 2026 as Restricted Stock Units, payable solely in Common Stock, pursuant to the Entegris, Inc. 2020 Stock Plan, which provides for the award of Restricted Stock Units to independent directors in consideration for services as such.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2013 Filed Sep 18, 2013 21:10 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 4,989 | $45.50 | $226,999.50 |
DisclosureSEC source: 0001179110-13-014321 · edgar.xml · nonDerivative · entry 3 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,590 Read SEC document |
| September 16, 2013 Filed Sep 18, 2013 21:10 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 2,200 | $28.32 | $62,309.50 |
DisclosureSEC source: 0001179110-13-014321 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2013 Filed Sep 18, 2013 21:10 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 4,100 | $27.29 | $111,905.40 |
DisclosureSEC source: 0001179110-13-014321 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2013 Filed Aug 20, 2013 21:10 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 1,312 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001179110-13-013321 · edgar.xml · derivative · entry 5 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,312 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2013 Filed Aug 20, 2013 21:10 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,270 | $43.01 | $54,622.70 |
DisclosureSEC source: 0001179110-13-013321 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,279 Read SEC document |
| August 19, 2013 Filed Aug 20, 2013 21:10 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 1,312 | $37.18 | $48,780.16 |
DisclosureSEC source: 0001179110-13-013321 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2013 Filed Aug 13, 2013 21:06 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 6,842 | $0.00 Strike: $24.07 | $0.00 |
DisclosureSEC source: 0001179110-13-013088 · edgar.xml · derivative · entry 14 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 6,842 shares Expires 2015-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2013 Filed Aug 13, 2013 21:06 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 5,006 | $45.01 | $225,307.04 |
DisclosureSEC source: 0001179110-13-013088 · edgar.xml · nonDerivative · entry 7 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,237 Read SEC document |
| August 12, 2013 Filed Aug 13, 2013 21:06 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 6,842 | $24.07 | $164,708.15 |
DisclosureSEC source: 0001179110-13-013088 · edgar.xml · nonDerivative · entry 6 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2013 Filed Aug 13, 2013 21:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 1,466 | $0.00 Strike: $45.06 | $0.00 |
DisclosureSEC source: 0001179110-13-013088 · edgar.xml · derivative · entry 13 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,466 Underlying: Common stock · 1,466 shares Expires 2014-02-19 F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 09, 2013 Filed Aug 13, 2013 21:06 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 1,734 | $0.00 Strike: $34.76 | $0.00 |
DisclosureSEC source: 0001179110-13-013088 · edgar.xml · derivative · entry 12 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,734 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2013 Filed Aug 13, 2013 21:06 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 2,158 | $0.00 Strike: $24.07 | $0.00 |
DisclosureSEC source: 0001179110-13-013088 · edgar.xml · derivative · entry 11 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,158 shares Expires 2015-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2013 Filed Aug 13, 2013 21:06 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 5,700 | $0.00 Strike: $22.94 | $0.00 |
DisclosureSEC source: 0001179110-13-013088 · edgar.xml · derivative · entry 10 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 5,700 shares Expires 2016-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2013 Filed Aug 13, 2013 21:06 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 2,618 | $45.06 | $117,967.08 |
DisclosureSEC source: 0001179110-13-013088 · edgar.xml · nonDerivative · entry 5 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,401 Read SEC document |
| August 09, 2013 Filed Aug 13, 2013 21:06 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 3,845 | $44.78 | $172,176.41 |
DisclosureSEC source: 0001179110-13-013088 · edgar.xml · nonDerivative · entry 4 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,019 Read SEC document |
| August 09, 2013 Filed Aug 13, 2013 21:06 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 1,734 | $34.76 | $60,281.12 |
DisclosureSEC source: 0001179110-13-013088 · edgar.xml · nonDerivative · entry 3 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2013 Filed Aug 13, 2013 21:06 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 2,158 | $24.07 | $51,949.75 |
DisclosureSEC source: 0001179110-13-013088 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2013 Filed Aug 13, 2013 21:06 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 5,700 | $22.94 | $130,761.99 |
DisclosureSEC source: 0001179110-13-013088 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2013 Filed Mar 12, 2013 21:09 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 496 | $37.50 | $18,600.00 |
DisclosureSEC source: 0001179110-13-004965 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,272 Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 22:06 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 1,479 | $36.73 | $54,323.67 |
DisclosureSEC source: 0001179110-13-004009 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,768 Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 00:05 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 421 | $37.58 | $15,821.18 |
DisclosureSEC source: 0001179110-13-003026 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,247 Read SEC document |
| February 14, 2013 Filed Feb 20, 2013 00:05 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 74,520 | $0.00 Strike: $35.88 | $0.00 |
DisclosureSEC source: 0001179110-13-003026 · edgar.xml · derivative · entry 5 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,520 Underlying: Common stock · 74,520 shares Expires 2023-02-13 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 24,840 on 02/14/2014, 24,840 on 02/14/2015, and 24,840 on 02/14/2016. Read SEC document |
| February 14, 2013 Filed Feb 20, 2013 00:05 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 36,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-003026 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,668 F1 · shares: These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 04, 2013 Filed Feb 6, 2013 22:11 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 3,309 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001179110-13-002023 · edgar.xml · derivative · entry 8 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,309 Underlying: Common stock · 3,309 shares Expires 2014-02-19 F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 04, 2013 Filed Feb 6, 2013 22:11 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 3,805 | $0.00 Strike: $29.40 | $0.00 |
DisclosureSEC source: 0001179110-13-002023 · edgar.xml · derivative · entry 7 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,805 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2013 Filed Feb 6, 2013 22:11 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 3,418 | $0.00 Strike: $31.95 | $0.00 |
DisclosureSEC source: 0001179110-13-002023 · edgar.xml · derivative · entry 6 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,418 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2013 Filed Feb 6, 2013 22:11 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 6,427 | $37.18 | $238,955.86 |
DisclosureSEC source: 0001179110-13-002023 · edgar.xml · nonDerivative · entry 3 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,188 Read SEC document |
| February 04, 2013 Filed Feb 6, 2013 22:11 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 3,805 | $29.40 | $111,878.80 |
DisclosureSEC source: 0001179110-13-002023 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2013 Filed Feb 6, 2013 22:11 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 3,418 | $31.95 | $109,218.09 |
DisclosureSEC source: 0001179110-13-002023 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.